JP2024509910A5 - - Google Patents

Info

Publication number
JP2024509910A5
JP2024509910A5 JP2023555203A JP2023555203A JP2024509910A5 JP 2024509910 A5 JP2024509910 A5 JP 2024509910A5 JP 2023555203 A JP2023555203 A JP 2023555203A JP 2023555203 A JP2023555203 A JP 2023555203A JP 2024509910 A5 JP2024509910 A5 JP 2024509910A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
region
seq
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023555203A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024509910A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2022/052119 external-priority patent/WO2022190009A1/en
Publication of JP2024509910A publication Critical patent/JP2024509910A/ja
Publication of JP2024509910A5 publication Critical patent/JP2024509910A5/ja
Pending legal-status Critical Current

Links

JP2023555203A 2021-03-09 2022-03-09 Mage-a4ペプチド-mhc抗原結合タンパク質 Pending JP2024509910A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163158691P 2021-03-09 2021-03-09
US63/158,691 2021-03-09
US202163172864P 2021-04-09 2021-04-09
US63/172,864 2021-04-09
PCT/IB2022/052119 WO2022190009A1 (en) 2021-03-09 2022-03-09 Mage-a4 peptide-mhc antigen binding proteins

Publications (2)

Publication Number Publication Date
JP2024509910A JP2024509910A (ja) 2024-03-05
JP2024509910A5 true JP2024509910A5 (cg-RX-API-DMAC10.html) 2025-03-17

Family

ID=80787264

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023555203A Pending JP2024509910A (ja) 2021-03-09 2022-03-09 Mage-a4ペプチド-mhc抗原結合タンパク質

Country Status (8)

Country Link
US (2) US11912771B2 (cg-RX-API-DMAC10.html)
EP (1) EP4304726A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024509910A (cg-RX-API-DMAC10.html)
KR (1) KR20230169944A (cg-RX-API-DMAC10.html)
AU (1) AU2022233285A1 (cg-RX-API-DMAC10.html)
CA (1) CA3210289A1 (cg-RX-API-DMAC10.html)
MX (1) MX2023010541A (cg-RX-API-DMAC10.html)
WO (1) WO2022190009A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12435444B2 (en) 2021-03-09 2025-10-07 Cdr-Life Ag Rabbit-derived antigen binding protein nucleic acid libraries and methods of making the same
EP4304726A1 (en) 2021-03-09 2024-01-17 CDR-Life AG Mage-a4 peptide-mhc antigen binding proteins
CA3240046A1 (en) 2021-12-14 2023-06-22 Cdr-Life Ag Dual mhc-targeting t cell engager
EP4587046A1 (en) 2022-09-14 2025-07-23 CDR-Life AG Mage-a4 peptide dual t cell engagers
CN119490592B (zh) * 2023-08-14 2025-11-18 东莞市朋志生物科技有限公司 一种抗κ型轻链抗体及其应用
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7199231B1 (en) 1991-05-23 2007-04-03 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-4 and 41 and uses thereof
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
AU5992999A (en) 1998-10-02 2000-04-26 Ludwig Institute For Cancer Research Tumor antigens and ctl clones isolated by a novel procedure
US7311914B2 (en) 2002-08-13 2007-12-25 Ludwig Institute For Cancer Research MAGE-A4 antigenic peptides and uses thereof
AU2003264009A1 (en) 2002-08-15 2004-03-03 Epitomics, Inc. Humanized rabbit antibodies
CN100415765C (zh) 2003-08-07 2008-09-03 宜康公司 兔单克隆抗体的人源化方法
US7807392B1 (en) 2003-09-15 2010-10-05 Celera Corporation Lung disease targets and uses thereof
CN101287831B (zh) 2005-09-13 2013-05-15 国立大学法人三重大学 T细胞受体和编码该受体的核酸
NZ579594A (en) 2007-03-12 2012-03-30 Esbatech Alcon Biomed Res Unit Sequence based engineering and optimization of single chain antibodies
NZ601583A (en) 2007-05-21 2013-08-30 Bristol Myers Squibb Co Novel rabbit antibody humanization methods and humanized rabbit antibodies
NZ581468A (en) 2007-06-25 2012-09-28 Esbatech Alcon Biomed Res Unit Methods of modifying antibodies, and modified antibodies with improved functional properties
CN101688200B (zh) 2007-06-25 2012-08-08 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 单链抗体的基于序列的改造和优化
PL2307455T3 (pl) 2008-06-25 2017-09-29 Esbatech, An Alcon Biomedical Research Unit Llc Optymalizacja rozpuszczalności cząsteczek immunowiążących
PL2307458T3 (pl) 2008-06-25 2018-08-31 Esbatech, An Alcon Biomedical Research Unit Llc Humanizacja przeciwciał króliczych z zastosowaniem uniwersalnego zrębu przeciwciała
CA2771575A1 (en) * 2009-08-29 2011-03-03 Abbott Laboratories Therapeutic dll4 binding proteins
WO2013048243A1 (en) 2011-09-29 2013-04-04 Apo-T B.V. Multi-specific binding molecules targeting aberrant cells
HK1245171A1 (zh) 2014-11-26 2018-08-24 Xencor, Inc. 结合cd3和cd38的异二聚体抗体
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
MX395611B (es) * 2016-04-08 2025-03-25 Adaptimmune Ltd Receptores de celulas t.
KR20190065189A (ko) 2016-04-08 2019-06-11 어댑티뮨 리미티드 T 세포 수용체
IL308831A (en) 2016-04-08 2024-01-01 Immunocore Ltd T cell receptors
HRP20251020T1 (hr) 2016-05-20 2025-10-24 Harpoon Therapeutics, Inc. Proteini s jednolančanim varijabilnim fragmentom koji vežu cd3
US11590098B2 (en) * 2016-09-06 2023-02-28 Mayo Foundation For Medical Education And Research Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
EP3601536A4 (en) 2017-03-20 2021-01-13 Genocea Biosciences, Inc. TREATMENT PROCEDURES
ES2991091T3 (es) * 2017-06-05 2024-12-02 Univ Mie Proteína de unión a antígeno que reconoce el péptido derivado de MAGE-A4
MX2020001879A (es) 2017-08-18 2020-07-29 Gritstone Oncology Inc Proteínas de fijación al antígeno que se dirigen a antígenos compartidos.
AU2018395397A1 (en) 2017-12-28 2020-08-06 Gritstone Bio, Inc. Antigen-binding proteins targeting shared antigens
GB201803750D0 (en) 2018-03-08 2018-04-25 Immunocore Ltd Method
JP7326764B2 (ja) 2018-03-09 2023-08-16 東ソー株式会社 腫瘍マーカーならびに腫瘍細胞を夾雑細胞と区別して回収および検出する方法
CA3102254A1 (en) 2018-06-04 2019-12-12 Apo-T B.V. Methods and means for attracting immune effector cells to tumor cells
CN108866098A (zh) 2018-07-27 2018-11-23 北京安斯晨睿生物科技有限公司 携带mage-a4突变抗原基因的重组腺相关病毒载体及其构建方法与应用
GB201819540D0 (en) 2018-11-30 2019-01-16 Adaptimmune Ltd T cell modification
GB201901306D0 (en) 2019-01-30 2019-03-20 Immunocore Ltd Multi-domain binding molecules
EP3714941A1 (en) * 2019-03-27 2020-09-30 Medigene Immunotherapies GmbH Mage-a4 tcrs
MX2021015946A (es) 2019-06-18 2022-04-18 Regeneron Pharma Receptores de linfocitos t de mage-a4 y métodos de uso de estos.
BR112022001194A2 (pt) * 2019-07-24 2022-06-07 Regeneron Pharma Receptores de antígeno quimérico com especificidade de mage a4 e usos dos mesmos
DE102019121007A1 (de) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Antigenbindende Proteine, die spezifisch an MAGE-A binden
US20210032370A1 (en) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Recruiting agent further binding an mhc molecule
CN110333352A (zh) 2019-08-07 2019-10-15 基因科技(上海)股份有限公司 肿瘤相关自身抗体及肿瘤标志物联合检测试剂盒
CN114828965B (zh) * 2019-12-18 2025-09-05 豪夫迈·罗氏有限公司 与hla-a2/mage-a4结合的抗体
CN115803340A (zh) 2020-04-24 2023-03-14 纪念斯隆凯特琳癌症中心 抗cd3抗体及其用途
CN116096754A (zh) 2020-05-04 2023-05-09 免疫里森公司 前体三特异性抗体构建体及其使用方法
EP4149631A1 (en) 2020-05-13 2023-03-22 Adaptimmune Limited Method of treatment of cancer or tumour
US20230190803A1 (en) 2020-05-13 2023-06-22 Adaptimmune Limited Method of treatment of cancer or tumour
CN118878693A (zh) 2020-11-23 2024-11-01 康诺亚生物医药科技(成都)有限公司 一种双特异性抗体及其用途
US12435444B2 (en) 2021-03-09 2025-10-07 Cdr-Life Ag Rabbit-derived antigen binding protein nucleic acid libraries and methods of making the same
EP4304726A1 (en) 2021-03-09 2024-01-17 CDR-Life AG Mage-a4 peptide-mhc antigen binding proteins
JP2024516308A (ja) 2021-05-04 2024-04-12 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Mage-a4特異性を有するキメラ抗原受容体及びその使用
WO2022262678A1 (zh) 2021-06-15 2022-12-22 盛禾(中国)生物制药有限公司 一种多特异性抗原结合蛋白及其应用
US20240327543A1 (en) 2021-08-02 2024-10-03 Shenghe (China) Biopharmaceutical Co., Ltd. Multispecific antigen-binding protein and use thereof
CN117730103A (zh) 2021-08-02 2024-03-19 盛禾(中国)生物制药有限公司 一种多特异性抗原结合蛋白及其应用
KR20240040097A (ko) 2021-08-04 2024-03-27 에이비프로 코퍼레이션 Cd3 표적화 항체 및 이의 용도
CA3231006A1 (en) 2021-09-17 2023-03-23 Adimab, Llc Anti-cd3 antibodies

Similar Documents

Publication Publication Date Title
JP7781243B2 (ja) ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法
US12258405B2 (en) CD3 antibody and pharmaceutical use thereof
JP2023515199A (ja) 免疫応答を調節するための材料及び方法
JP2019524693A5 (cg-RX-API-DMAC10.html)
CN112969476A (zh) 多特异性蛋白分子
TW202327649A (zh) Pvrig/tigit結合蛋白聯合免疫檢查點抑制劑用於治療癌症
JP2024509910A (ja) Mage-a4ペプチド-mhc抗原結合タンパク質
CN116209680A (zh) 与人CD3ε结合的新型人抗体
JP2022516351A (ja) 抗tigit抗体
CN117083299A (zh) Cldn18.2抗原结合蛋白及其用途
CN114829405B (zh) 抗bcma/抗4-1bb双特异性抗体及其用途
JP2025534237A (ja) Mage-a4ペプチドデュアルt細胞エンゲージャー
CN116547300B (zh) 双特异性抗体及其应用
CN115746144B (zh) 抗tigit-pd1双特异性抗体及其应用
CN117120470A (zh) Pd-1结合蛋白及其医药用途
CN117715940A (zh) 抗trem-1抗体
CN116813786B (zh) 抗cd73抗体及其应用
CN120137042A (zh) 一种抗st2单克隆抗体与应用
WO2025025190A1 (zh) 抗cd73抗体及其应用
WO2024152962A1 (zh) 抗tt3的人源化抗体及其应用
WO2024245441A1 (zh) 靶向cd39的抗原结合蛋白及其应用
WO2024078558A1 (zh) 抗cd100抗体及其用途
WO2025238157A1 (en) Multispecific binding agent suitable for use in cancer immune therapy
WO2024164807A1 (zh) 多特异性抗体及其应用
CN121851174A (zh) 双特异性抗cd3/cd20抗体及其在b细胞淋巴瘤中的应用